Evonile Pharma Ltd reports Q2 FY27 revenue of ₹56.1 crore and operating EBITDA loss of ₹31.8 crore.
- Q2 operating EBITDA margin was approximately -56.7%; Q2 net profit was not stated.
- H1 FY27 revenue was ₹159.9 crore, with a net loss of ₹45.3 crore.
- The company cited one-time transition costs and upfront organisational investment; prior-year results are not comparable following a change in control and business model.
